PedAM

Pediatric Disease Annotations & Medicines


	anoxia

Disease ID	1661
Disease	anoxia
Definition	Relatively complete absence of oxygen in one or more tissues.
Synonym	absence oxygen deficiency, oxygen hypoxia hypoxia [disease/finding] oxygen deficiency oxygen supply absent oxygen supply absent (finding)
UMLS	C0003130
MeSH	D000860
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:250) C0020542 \| pulmonary hypertension \| 47 C0022116 \| ischemia \| 34 C0020538 \| hypertension \| 27 C0037315 \| sleep apnea \| 20 C0006142 \| breast cancer \| 19 C0028754 \| obesity \| 15 C0011570 \| depression \| 15 C0520679 \| obstructive sleep apnea \| 14 C0011847 \| diabetes \| 12 C0002871 \| anemia \| 12 C0042373 \| vascular disease \| 12 C0024115 \| lung disease \| 10 C0020456 \| hyperglycemia \| 10 C1145670 \| respiratory failure \| 10 C0034063 \| pulmonary edema \| 10 C0017636 \| glioblastoma \| 9 C0001125 \| lactic acidosis \| 9 C1619734 \| pulmonary arterial hypertension \| 9 C0376358 \| prostate cancer \| 9 C0032051 \| placental insufficiency \| 9 C0022116 \| ischaemia \| 8 C0024115 \| pulmonary disease \| 8 C0037315 \| sleep apnea syndrome \| 7 C0600260 \| obstructive pulmonary disease \| 7 C0024117 \| chronic obstructive pulmonary disease \| 7 C0018801 \| heart failure \| 7 C0018799 \| heart disease \| 6 C0020598 \| hypoglycemia \| 6 C0520679 \| obstructive sleep apnea syndrome \| 6 C0042373 \| vascular diseases \| 6 C0007222 \| cardiovascular disease \| 6 C0007113 \| rectal cancer \| 6 C0040053 \| thrombosis \| 6 C0024115 \| lung diseases \| 6 C0007222 \| cardiovascular diseases \| 5 C0235974 \| pancreatic cancer \| 5 C0007785 \| cerebral ischemia \| 5 C0002871 \| anaemia \| 5 C0007102 \| colon cancer \| 5 C0024623 \| gastric cancer \| 5 C0037315 \| sleep apnoea \| 5 C0019204 \| hepatocellular carcinoma \| 4 C0004096 \| asthma \| 4 C0025202 \| melanoma \| 4 C0009402 \| colorectal cancer \| 4 C0007131 \| nsclc \| 4 C0159020 \| neonatal seizures \| 4 C0027819 \| neuroblastoma \| 4 C0152021 \| congenital heart disease \| 4 C0032914 \| preeclampsia \| 4 C0022658 \| kidney disease \| 4 C0024117 \| chronic obstructive pulmonary disease (copd) \| 4 C0032461 \| polycythemia \| 4 C0035309 \| retinopathy \| 4 C0024530 \| malaria \| 3 C0151744 \| myocardial ischemia \| 3 C0035229 \| respiratory insufficiency \| 3 C0005684 \| bladder cancer \| 3 C0242379 \| lung cancer \| 3 C0003467 \| anxiety \| 3 C0002895 \| sickle cell disease \| 3 C0027051 \| myocardial infarct \| 3 C0023890 \| liver cirrhosis \| 3 C0011860 \| type 2 diabetes \| 3 C0007134 \| renal cell carcinoma \| 3 C0020456 \| hyperglycaemia \| 3 C0004153 \| atherosclerosis \| 3 C0035309 \| retinal disease \| 3 C0026846 \| muscle atrophy \| 3 C1704437 \| respiratory distress syndrome \| 3 C0013537 \| eclampsia \| 3 C0032285 \| pneumonia \| 3 C0022661 \| chronic kidney disease \| 3 C0014544 \| epilepsy \| 3 C0149925 \| small cell lung cancer \| 2 C0398623 \| hypercoagulable state \| 2 C0032326 \| pneumothorax \| 2 C1261473 \| sarcomas \| 2 C0162429 \| malnutrition \| 2 C0520679 \| obstructive sleep apnoea \| 2 C0002395 \| alzheimer's disease \| 2 C0023890 \| cirrhosis \| 2 C0035335 \| retinoblastoma \| 2 C0007137 \| squamous cell carcinoma \| 2 C0679466 \| cognitive deficits \| 2 C0027051 \| myocardial infarction \| 2 C0003864 \| arthritis \| 2 C0036341 \| schizophrenia \| 2 C0282193 \| iron overload \| 2 C0155765 \| microangiopathy \| 2 C0035078 \| renal failure \| 2 C1140680 \| ovarian cancer \| 2 C0034069 \| lung fibrosis \| 2 C0035204 \| respiratory disease \| 2 C0020538 \| systemic hypertension \| 2 C0851578 \| sleep disorders \| 2 C0037315 \| sleep-disordered breathing \| 2 C1140680 \| ovarian ca \| 2 C0011849 \| diabetes mellitus \| 2 C0302592 \| cervical ca \| 2 C1621958 \| glioblastoma multiforme \| 2 C0007134 \| renal cell carcinomas \| 2 C0035258 \| restless legs syndrome \| 2 C0007789 \| cerebral palsy \| 2 C0024115 \| pulmonary disorders \| 2 C0878544 \| cardiomyopathy \| 2 C0023895 \| liver disease \| 2 C0006271 \| bronchiolitis \| 2 C0206062 \| interstitial lung disease \| 2 C0029463 \| osteosarcoma \| 2 C0007131 \| non-small cell lung cancer \| 2 C0302592 \| cervical carcinoma \| 2 C0035258 \| restless legs \| 2 C0035309 \| retinal diseases \| 2 C0040053 \| thrombus \| 2 C0026764 \| myeloma \| 2 C0085669 \| acute leukemia \| 1 C0035258 \| restless legs syndrome (rls) \| 1 C0032310 \| viral pneumonia \| 1 C0740457 \| renal cancer \| 1 C0039730 \| thalassemia \| 1 C1527311 \| brain swelling \| 1 C0026846 \| muscle wasting \| 1 C0013384 \| abnormal movements \| 1 C0476089 \| endometrial cancer \| 1 C0751955 \| brain infarct \| 1 C0020598 \| hypoglycaemia \| 1 C0034069 \| pulmonary fibrosis \| 1 C0001418 \| adenocarcinoma \| 1 C0002766 \| analgesia \| 1 C0004045 \| birth asphyxia \| 1 C0015464 \| facial nerve palsy \| 1 C0025637 \| methemoglobinemia \| 1 C0017658 \| glomerulonephritis \| 1 C0007682 \| cns disorder \| 1 C0032827 \| k deficiency \| 1 C0812413 \| malignant pleural mesothelioma \| 1 C0023903 \| liver tumor \| 1 C0398623 \| hypercoagulability \| 1 C0031099 \| periodontitis \| 1 C0008495 \| chorioamnionitis \| 1 C0751955 \| brain infarction \| 1 C0152013 \| lung adenocarcinoma \| 1 C0019158 \| hepatitis \| 1 C0032285 \| pneumonitis \| 1 C0850572 \| colonic adenoma \| 1 C0699790 \| colon carcinoma \| 1 C0006111 \| brain disorders \| 1 C0085207 \| maternal diabetes \| 1 C0033375 \| prolactinomas \| 1 C0014859 \| esophageal cancer \| 1 C0017636 \| glioblastomas \| 1 C0028756 \| severe obesity \| 1 C0020428 \| hyperaldosteronism \| 1 C0007137 \| squamous cell cancer \| 1 C0013421 \| dystonia \| 1 C0026764 \| multiple myeloma \| 1 C0002878 \| haemolytic anaemia \| 1 C0282488 \| interstitial cystitis \| 1 C0041296 \| tuberculosis \| 1 C0019829 \| hodgkin lymphoma \| 1 C0162871 \| abdominal aortic aneurysm \| 1 C0264716 \| chronic heart failure \| 1 C0026640 \| oral cancer \| 1 C0279626 \| esophageal squamous cell carcinoma \| 1 C1318533 \| secondary polycythemia \| 1 C0405581 \| testicular dysfunction \| 1 C1527349 \| breast ductal carcinoma \| 1 C0151740 \| intracranial hypertension \| 1 C0042373 \| vascular disorders \| 1 C0035305 \| retinal detachment \| 1 C0456909 \| blindness \| 1 C0019204 \| hepatoma \| 1 C0346647 \| pancreatic cancers \| 1 C0242342 \| sheehan syndrome \| 1 C0004623 \| bacterial infection \| 1 C0037315 \| sleep apneas \| 1 C0011991 \| diarrhoea \| 1 C0007137 \| squamous cell carcinomas \| 1 C0948265 \| metabolic syndrome \| 1 C0024586 \| carcinoid syndrome \| 1 C0011854 \| type 1 diabetes \| 1 C0029443 \| osteomyelitis \| 1 C0008312 \| biliary cirrhosis \| 1 C0553580 \| ewing sarcoma \| 1 C0278701 \| gastric adenocarcinoma \| 1 C0034072 \| cor pulmonale \| 1 C0149931 \| migraine \| 1 C0019348 \| herpes simplex \| 1 C0025149 \| medulloblastoma \| 1 C0020255 \| hydrocephalus \| 1 C0085084 \| motor neurone disease \| 1 C0023895 \| liver diseases \| 1 C0042373 \| vascular disorder \| 1 C0003850 \| arteriosclerosis \| 1 C0035304 \| retinal degeneration \| 1 C0007785 \| cerebral infarction \| 1 C0242350 \| erectile dysfunction \| 1 C0154830 \| proliferative diabetic retinopathy \| 1 C0007138 \| urothelial carcinoma \| 1 C0007222 \| cardiovascular disorders \| 1 C0023903 \| hepatic cancer \| 1 C0022408 \| joint disease \| 1 C0009319 \| colitis \| 1 C0546837 \| oesophageal cancer \| 1 C0699791 \| gastric carcinoma \| 1 C0027719 \| nephrosclerosis \| 1 C0027051 \| heart attack \| 1 C0018802 \| congestive heart failure \| 1 C0031039 \| pericardial effusion \| 1 C0028790 \| cerebral artery occlusion \| 1 C0751711 \| anterior ischemic optic neuropathy \| 1 C0024305 \| non-hodgkin lymphoma \| 1 C0740487 \| maxillary sinus carcinoma \| 1 C0042345 \| varicosity \| 1 C0025048 \| meconium aspiration \| 1 C0007785 \| cerebral infarct \| 1 C0007107 \| laryngeal cancer \| 1 C0010068 \| coronary artery disease \| 1 C0004114 \| astrocytic tumor \| 1 C1527311 \| brain edema \| 1 C0024299 \| lymphoma \| 1 C0006111 \| brain disorder \| 1 C0025202 \| melanomas \| 1 C0023891 \| alcoholic liver cirrhosis \| 1 C0476089 \| endometrial ca \| 1 C1261473 \| sarcoma \| 1 C0032319 \| pneumopericardium \| 1 C0151744 \| myocardial ischaemia \| 1 C0497327 \| dementia \| 1 C0004045 \| neonatal asphyxia \| 1 C0011884 \| diabetic retinopathy \| 1 C0006287 \| bronchopulmonary dysplasia \| 1 C0279702 \| clear cell renal cell carcinoma \| 1 C0013990 \| emphysema \| 1 C0024115 \| pulmonary diseases \| 1 C0028754 \| adiposity \| 1 C0043117 \| idiopathic thrombocytopenic purpura \| 1 C0151650 \| renal fibrosis \| 1 C0155320 \| cortical blindness \| 1 C0027708 \| wilms' tumour \| 1 C0004936 \| mental disorders \| 1 C0026603 \| motion sickness \| 1 C0238033 \| male breast cancer \| 1 C0740394 \| hyperuricemia \| 1 C1527407 \| eosinophilic pneumonia \| 1 C0008487 \| chordoma \| 1 C0032285 \| pulmonary inflammation \| 1 C0013384 \| abnormal movement \| 1 C0041696 \| major depression \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:33) SOD2 \| 6648 \| CTD_human POMC \| 5443 \| CTD_human NOS3 \| 4846 \| CTD_human ACTB \| 60 \| CTD_human GNAS \| 2778 \| CTD_human APOA1 \| 335 \| CTD_human CS \| 1431 \| CTD_human PLAT \| 5327 \| CTD_human ACADVL \| 37 \| CTD_human RPS2 \| 6187 \| CTD_human PDYN \| 5173 \| CTD_human ALDOB \| 229 \| CTD_human NOS1 \| 4842 \| CTD_human BDNF \| 627 \| CTD_human NPPA \| 4878 \| CTD_human MPO \| 4353 \| CTD_human GAPDH \| 2597 \| CTD_human NME1 \| 4830 \| CTD_human ALDH1L1 \| 10840 \| CTD_human ADK \| 132 \| CTD_human EGR1 \| 1958 \| CTD_human AHCY \| 191 \| CTD_human PCK2 \| 5106 \| CTD_human TFPI \| 7035 \| CTD_human CTRB1 \| 1504 \| CTD_human ESD \| 2098 \| CTD_human ATP5B \| 506 \| CTD_human ATF4 \| 468 \| CTD_human TKT \| 7086 \| CTD_human CA9 \| 768 \| CTD_human SARDH \| 1757 \| CTD_human CPA2 \| 1358 \| CTD_human RPS14 \| 6208 \| CTD_human
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:5) 1636 \| ACE \| infer 3091 \| HIF1A \| infer 6390 \| SDHB \| infer 6391 \| SDHC \| infer 6392 \| SDHD \| infer
Text Mined Gene	(Waiting for update.)
Locus	(Waiting for update.)

Disease ID	1661
Disease	anoxia
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:237) HP:0002664 \| Neoplasia \| 172 HP:0002092 \| Pulmonary artery hypertension \| 48 HP:0002104 \| Absence of spontaneous respiration \| 42 HP:0001941 \| acidemia \| 32 HP:0000822 \| Hypertension \| 27 HP:0010535 \| Sleep apnea \| 25 HP:0012416 \| Hypercarbia \| 20 HP:0000969 \| Dropsy \| 19 HP:0003002 \| Breast carcinoma \| 19 HP:0001903 \| Anemia \| 17 HP:0001513 \| Obesity \| 15 HP:0000716 \| Depression \| 15 HP:0002870 \| Obstructive sleep apnea \| 14 HP:0000718 \| Aggressive behaviour \| 12 HP:0003287 \| Abnormality of mitochondrial metabolism \| 11 HP:0001511 \| Prenatal onset growth retardation \| 11 HP:0009733 \| Glioma \| 10 HP:0100598 \| Pulmonary oedema \| 10 HP:0000855 \| Insulin resistance \| 10 HP:0002791 \| Under breathing \| 10 HP:0002615 \| Low blood pressure \| 10 HP:0002878 \| Respiratory failure \| 10 HP:0003074 \| High blood glucose \| 10 HP:0001298 \| Encephalopathy \| 10 HP:0012125 \| Prostate cancer \| 9 HP:0003128 \| Lactic acidosis \| 9 HP:0100843 \| Glioblastoma \| 9 HP:0002098 \| Respiratory distress \| 8 HP:0001942 \| Metabolic acidosis \| 8 HP:0001297 \| Cerebral vascular events \| 8 HP:0001635 \| Congestive heart failure \| 7 HP:0002045 \| Abnormally low body temperature \| 7 HP:0100543 \| Cognitive deficits \| 7 HP:0001943 \| Hypoglycemia \| 7 HP:0006510 \| Chronic obstructive pulmonary disease \| 7 HP:0030731 \| Carcinoma \| 7 HP:0001662 \| Bradycardia \| 7 HP:0012378 \| Fatigue \| 6 HP:0012418 \| Low blood oxygen level \| 5 HP:0002894 \| Neoplasia of the pancreas \| 5 HP:0001901 \| Abnormally shaped erythrocytes \| 5 HP:0012126 \| Gastric cancer \| 5 HP:0002354 \| Memory loss \| 5 HP:0100806 \| Sepsis \| 5 HP:0001714 \| Ventricular hypertrophy \| 5 HP:0003003 \| Colon cancer \| 5 HP:0002094 \| Dyspnea \| 5 HP:0001824 \| Weight loss \| 5 HP:0002637 \| Brain ischemia \| 5 HP:0012531 \| Pain \| 5 HP:0001667 \| Right ventricular hypertrophy \| 5 HP:0003006 \| Neuroblastoma \| 4 HP:0040213 \| Hypopnea \| 4 HP:0002781 \| Upper airway obstruction \| 4 HP:0000488 \| Noninflammatory retina disease \| 4 HP:0100602 \| Pre-eclampsia \| 4 HP:0030692 \| Brain tumor \| 4 HP:0003202 \| Neurogenic muscle atrophy, especially in the lower limbs \| 4 HP:0001279 \| Syncope \| 4 HP:0012735 \| Coughing \| 4 HP:0012474 \| Obstructed carotid artery \| 4 HP:0001259 \| Coma \| 4 HP:0001518 \| Small for gestational age \| 4 HP:0002861 \| Melanoma \| 4 HP:0001397 \| Hepatic steatosis \| 4 HP:0001945 \| Fever \| 4 HP:0001402 \| Hepatocellular carcinoma \| 4 HP:0002099 \| Asthma \| 4 HP:0005584 \| Renal cell carcinoma \| 3 HP:0001694 \| Right-to-left shunt \| 3 HP:0002181 \| Cerebral edema \| 3 HP:0012622 \| Chronic kidney disease \| 3 HP:0001250 \| Seizures \| 3 HP:0030759 \| Fat cell hypertrophy \| 3 HP:0007185 \| Loss of consciousness \| 3 HP:0006528 \| Chronic lung disease \| 3 HP:0009725 \| Bladder neoplasm \| 3 HP:0002090 \| Pneumonia \| 3 HP:0001658 \| Myocardial infarction \| 3 HP:0002621 \| Atherosclerosis \| 3 HP:0000739 \| Anxiety \| 3 HP:0002093 \| progressive respiratory failure \| 3 HP:0011675 \| Arrhythmias \| 3 HP:0100601 \| Eclampsia \| 3 HP:0005972 \| Respiratory acidosis \| 3 HP:0002669 \| Osteosarcoma \| 2 HP:0006530 \| Interstitial lung disease \| 2 HP:0100273 \| Colon tumor \| 2 HP:0001944 \| Dehydration \| 2 HP:0002860 \| Squamous cell carcinoma \| 2 HP:0030357 \| Small cell lung carcinoma \| 2 HP:0000083 \| Renal insufficiency \| 2 HP:0001695 \| Cardiac arrest \| 2 HP:0011106 \| Depleted blood volume \| 2 HP:0100753 \| Schizophrenia \| 2 HP:0011950 \| Bronchiolitis \| 2 HP:0002180 \| Neurodegeneration \| 2 HP:0100021 \| Cerebral palsy \| 2 HP:0001369 \| Arthritis \| 2 HP:0001394 \| Hepatic cirrhosis \| 2 HP:0000819 \| Diabetes mellitus \| 2 HP:0000961 \| Cyanosis \| 2 HP:0030149 \| Cardiovascular shock \| 2 HP:0001263 \| Developmental retardation \| 2 HP:0001919 \| Acute renal failure \| 2 HP:0001510 \| Growth deficiency \| 2 HP:0002789 \| Increased respiratory rate or depth of breathing \| 2 HP:0100750 \| Pulmonary atelectasis \| 2 HP:0009919 \| Retinoblastoma \| 2 HP:0012452 \| Restless legs \| 2 HP:0001638 \| Cardiomyopathy \| 2 HP:0002107 \| Collapsed lung \| 2 HP:0004395 \| Malnutrition \| 2 HP:0030830 \| Crackles \| 2 HP:0001948 \| Alkalosis \| 2 HP:0011967 \| Hypocupremia \| 2 HP:0002883 \| Rapid breathing \| 2 HP:0002138 \| Subarachnoid hemorrhage \| 2 HP:0030666 \| Retinal neovascularisation \| 2 HP:0003764 \| Naevus \| 2 HP:0012174 \| Glioblastoma multiforme \| 2 HP:0100526 \| Neoplasm of the lung \| 2 HP:0030358 \| Non-small cell lung carcinoma \| 2 HP:0001631 \| Atria septal defect \| 2 HP:0001649 \| Tachycardia \| 2 HP:0000980 \| Pallor \| 2 HP:0001268 \| Mental deterioration \| 1 HP:0003470 \| Inability to move \| 1 HP:0001657 \| Prolonged QT interval \| 1 HP:0001627 \| Congenital heart defects \| 1 HP:0002597 \| Abnormality of blood vessels \| 1 HP:0012254 \| Ewing's sarcoma \| 1 HP:0002202 \| Pleural effusion \| 1 HP:0002149 \| Hyperuricemia \| 1 HP:0001698 \| Pericardial effusions \| 1 HP:0030774 \| Mitochondrial swelling \| 1 HP:0012539 \| Non-Hodgkin lymphoma \| 1 HP:0012115 \| Liver inflammation \| 1 HP:0001878 \| Haemolytic anaemia \| 1 HP:0000113 \| Polycystic kidney dysplasia \| 1 HP:0001648 \| Cor pulmonale \| 1 HP:0012119 \| Methemoglobinemia \| 1 HP:0002488 \| Acute leukemias \| 1 HP:0000099 \| Glomerular nephritis \| 1 HP:0002613 \| Biliary cirrhosis \| 1 HP:0000802 \| Erectile dysfunction \| 1 HP:0001332 \| Dystonia \| 1 HP:0030828 \| Wheezing \| 1 HP:0002076 \| Migraine headaches \| 1 HP:0100785 \| Insomnia \| 1 HP:0001399 \| Liver failure \| 1 HP:0003474 \| Sensory impairment \| 1 HP:0001317 \| Abnormality of the cerebellum \| 1 HP:0004953 \| Abdominal aortic aneurysm \| 1 HP:0009741 \| Thickening of kidney artiries \| 1 HP:0012118 \| Cancer of the larynx \| 1 HP:0003201 \| Rhabdomyolysis \| 1 HP:0000546 \| Retinal degeneration \| 1 HP:0100695 \| Lipedema \| 1 HP:0100570 \| Carcinoid tumor \| 1 HP:0006543 \| Cardiorespiratory arrest \| 1 HP:0002885 \| Medulloblastoma \| 1 HP:0001712 \| Left ventricular hypertrophy \| 1 HP:0002754 \| Bone infection \| 1 HP:0000704 \| Pyorrhea \| 1 HP:0100242 \| Sarcoma \| 1 HP:0000711 \| Restlessness \| 1 HP:0011096 \| Demyelination \| 1 HP:0002459 \| Dysautonomia \| 1 HP:0001395 \| Hepatic fibrosis \| 1 HP:0100724 \| Hypercoagulability \| 1 HP:0000365 \| Hearing impairment \| 1 HP:0002902 \| Hyponatremia \| 1 HP:0001900 \| Increased hemoglobin \| 1 HP:0006770 \| Nonpapillary renal cell carcinoma \| 1 HP:0001708 \| Impaired right ventricular function \| 1 HP:0001289 \| Confusion \| 1 HP:0007340 \| Lower limb weakness \| 1 HP:0002668 \| Paragangliomas \| 1 HP:0100520 \| Oliguria \| 1 HP:0002647 \| Aortic dissection \| 1 HP:0000752 \| Hyperactive behavior \| 1 HP:0000708 \| Behavioral problems \| 1 HP:0012466 \| Chronic respiratory acidosis \| 1 HP:0002896 \| Liver cancer \| 1 HP:0004448 \| Fulminant hepatic failure \| 1 HP:0002315 \| Headaches \| 1 HP:0002171 \| Cerebral gliosis \| 1 HP:0007634 \| Nonarteritic anterior ischemic optic neuropathy \| 1 HP:0000078 \| Genital abnormalities \| 1 HP:0000859 \| Mineralocorticoid excess \| 1 HP:0012189 \| Hodgkin disease \| 1 HP:0009800 \| gestational diabetes \| 1 HP:0002960 \| Autoimmune condition \| 1 HP:0012288 \| Head and neck tumor \| 1 HP:0002155 \| Increased triglycerides \| 1 HP:0100704 \| Cortical visual impairment \| 1 HP:0002148 \| Hypophosphataemia \| 1 HP:0001058 \| Poor wound healing \| 1 HP:0001371 \| Flexion contractures of joints \| 1 HP:0030078 \| Lung adenocarcinoma \| 1 HP:0000618 \| Blindness \| 1 HP:0012399 \| Bedsore \| 1 HP:0010628 \| Facial palsy, unilateral or bilateral \| 1 HP:0010762 \| Chordoma \| 1 HP:0030005 \| Capillary leak \| 1 HP:0002634 \| Arteriosclerosis \| 1 HP:0001249 \| Mental retardation \| 1 HP:0001000 \| Pigmentary changes \| 1 HP:0010536 \| Central sleep apnoea \| 1 HP:0005110 \| Atrial fibrillation \| 1 HP:0005943 \| Respiratory arrest \| 1 HP:0002877 \| Nocturnal under breathing \| 1 HP:0002500 \| Leukoaraiosis \| 1 HP:0100615 \| Neoplasm of the ovary \| 1 HP:0000726 \| Dementia \| 1 HP:0000734 \| Disinhibition \| 1 HP:0100013 \| Tumours of the breast \| 1 HP:0002583 \| Colitis \| 1 HP:0012768 \| Neonatal asphyxia \| 1 HP:0100749 \| Thoracic pain \| 1 HP:0000238 \| Nonsyndromal hydrocephalus \| 1 HP:0000541 \| Detached retina \| 1 HP:0000092 \| Tubular atrophy \| 1 HP:0005162 \| Left ventricular impairment \| 1 HP:0000107 \| Renal cyst \| 1 HP:0002665 \| Lymphoma \| 1 HP:0030760 \| Kidney fibrosis \| 1 HP:0010885 \| Aseptic necrosis \| 1 HP:0001950 \| Respiratory alkalosis \| 1 HP:0003712 \| Hypertrophic muscles \| 1 HP:0006775 \| Multiple myeloma \| 1 HP:0200114 \| Metabolic alkalosis \| 1 HP:0002206 \| Pulmonary fibrosis \| 1 HP:0002097 \| Pulmonary emphysema \| 1 HP:0001677 \| Coronary artery disease \| 1 HP:0002516 \| Intracranial pressure elevation \| 1

Disease ID	1661
Disease	anoxia
Manually Symptom	(Waiting for update.)
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:4) C0085584 \| encephalopathy \| 2 C0035229 \| respiratory insufficiency \| 1 C0011570 \| depression \| 1 C0235169 \| excitability \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:0)
(Waiting for update.)

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:35)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0003130	acetaminophen	D000082	103-90-2	anoxia	MESH:D000860	marker/mechanism	7585440
C0003130	allopurinol	D000493	315-30-0	anoxia	MESH:D000860	therapeutic	9840616
C0003130	alprazolam	D000525	28981-97-7	anoxia	MESH:D000860	marker/mechanism	11815692
C0003130	amitriptyline	D000639	50-48-6	anoxia	MESH:D000860	marker/mechanism	12212966
C0003130	bleomycin	D001761	11056-06-7	anoxia	MESH:D000860	marker/mechanism	15782499
C0003130	bupivacaine	D002045	2180-92-9	anoxia	MESH:D000860	marker/mechanism	7059040
C0003130	cefotiam	D015310	61622-34-2	anoxia	MESH:D000860	marker/mechanism	15221158
C0003130	chloroquine	D002738	1954/5/7	anoxia	MESH:D000860	marker/mechanism	2290474
C0003130	codeine	D003061	76-57-3	anoxia	MESH:D000860	marker/mechanism	7532552
C0003130	cyproheptadine	D003533	129-03-3	anoxia	MESH:D000860	therapeutic	2367283
C0003130	diltiazem	D004110	42399-41-7	anoxia	MESH:D000860	marker/mechanism	12629592
C0003130	diltiazem	D004110	42399-41-7	anoxia	MESH:D000860	therapeutic	1472086
C0003130	doxapram	D004315	309-29-5	anoxia	MESH:D000860	therapeutic	8737758
C0003130	enalapril	D004656	75847-73-3	anoxia	MESH:D000860	marker/mechanism	21263376
C0003130	felbamate	C047360	25451-15-4	anoxia	MESH:D000860	therapeutic	8232947
C0003130	fenfluramine	D005277	458-24-2	anoxia	MESH:D000860	marker/mechanism	2367283
C0003130	fluorouracil	D005472	51-21-8	anoxia	MESH:D000860	marker/mechanism	19127237
C0003130	gabapentin	C040029	60142-96-3	anoxia	MESH:D000860	therapeutic	12770949
C0003130	gemcitabine	C056507	103882-84-4	anoxia	MESH:D000860	therapeutic	20531411
C0003130	indomethacin	D007213	53-86-1	anoxia	MESH:D000860	marker/mechanism	3579483
C0003130	lidocaine	D008012	137-58-6	anoxia	MESH:D000860	marker/mechanism	9803439
C0003130	liposomal amphotericin b	C068538	-	anoxia	MESH:D000860	marker/mechanism	9758315
C0003130	methadone	D008691	76-99-3	anoxia	MESH:D000860	marker/mechanism	16997682
C0003130	morphine	D009020	57-27-2	anoxia	MESH:D000860	marker/mechanism	10411768
C0003130	nicotine	D009538	-	anoxia	MESH:D000860	marker/mechanism	14980338
C0003130	nimodipine	D009553	66085-59-4	anoxia	MESH:D000860	marker/mechanism	15359206
C0003130	nitric oxide	D009569	10102-43-9	anoxia	MESH:D000860	therapeutic	11195228
C0003130	nitroprusside	D009599	15078-28-1	anoxia	MESH:D000860	marker/mechanism	2084452
C0003130	norepinephrine	D009638	51-41-2	anoxia	MESH:D000860	marker/mechanism	11311734
C0003130	phenylephrine	D010656	59-42-7	anoxia	MESH:D000860	therapeutic	7532552
C0003130	propylthiouracil	D011441	51-52-5	anoxia	MESH:D000860	marker/mechanism	10846402
C0003130	ribavirin	D012254	36791-04-5	anoxia	MESH:D000860	marker/mechanism	16002945
C0003130	spironolactone	D013148	1952/1/7	anoxia	MESH:D000860	marker/mechanism	20228418
C0003130	sulindac	D013467	38194-50-2	anoxia	MESH:D000860	marker/mechanism	19074762
C0003130	vitamin e	D014810	1406-18-4	anoxia	MESH:D000860	therapeutic	8552434

FDA approved drug and dosage information(Total Drugs:12)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D000860	neurontin	gabapentin	100MG	CAPSULE;ORAL	Prescription	AB	Yes	No
MESH:D000860	neurontin	gabapentin	600MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D000860	neurontin	gabapentin	250MG/5ML	SOLUTION;ORAL	Prescription	AA	Yes	Yes
MESH:D000860	neurontin	gabapentin	0	SOLUTION; ORAL	Prescription	None	No	No
MESH:D000860	neurontin	gabapentin	600MG	TABLET; ORAL	Prescription	None	No	No
MESH:D000860	neurontin	gabapentin	800MG	CAPSULE; ORAL	Prescription	None	No	No
MESH:D000860	neurontin	gabapentin	250MG/5ML	SOLUTION; ORAL	Prescription	None	No	No
MESH:D000860	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D000860	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D000860	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D000860	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D000860	inomax	nitric oxide	100PPM Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	GAS;INHALATION	Discontinued	None	Yes	No

FDA labeling changes(Total Drugs:12)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D000860	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D000860	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D000860	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D000860	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D000860	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D000860	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D000860	12/10/2000	neurontin	gabapentin	Adjunctive therapy in the treatment of partial seizures	Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children	Labeling	B	-	-	-	Parke-Davis	2/2/2000	FALSE'
MESH:D000860	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D000860	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D000860	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D000860	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D000860	12/21/2010	inomax	nitric oxide	Prevention of bronchopulmonary dysplasia	INOmax is not indicated for prevention of BPD in preterm neonates d 34 weeks gestational age.Efficacy for the prevention of BPD in preterm infants was not established in three ldouble-blind, placebo-controlled clinical trials in a total of 2,149 preterm infants Information on clinical trials, adverse reaction	Labeling	B	-	-	-	INO Therapeutics	2/11/2010	FALSE'